WS Investor
01 Oct 2026, 17:47
Pfizer’s Tilrekimig Shows Strong Skin Clearance in Phase 2 Atopic Dermatitis Study
Pfizer reported positive Phase 2 results for tilrekimig, an investigational trispecific antibody being developed for moderate-to-severe atopic dermatitis. The study met its primary endpoint, with all evaluated doses producing statistically significant improvements in EASI-75 skin-clearance rates versus placebo at Week 16.
In Stage 1, 62.5% of patients receiving tilrekimig 450 mg every two weeks achieved EASI-75, compared with 19.9% for placebo. In Stage 2, EASI-75 rates were 58.5% for the 400 mg monthly dose, 61.0% for 200 mg and 47.8% for 50 mg, versus 9.1% for placebo.
Tilrekimig is designed to simultaneously block IL-4, IL-13 and TSLP, targeting multiple pathways involved in type 2 inflammation. Pfizer is also developing the drug with an extended half-life intended to support monthly dosing.
Secondary and exploratory endpoints were also encouraging. Around 26% to 30% of treated patients achieved clear or almost-clear skin depending on dose and study stage, while itch reduction was meaningfully greater than with placebo.
Pfizer said the treatment was generally well tolerated, with no dose-dependent safety signals and no treatment-related serious adverse events reported in the first two stages.
The company has already started Phase 3 trials in atopic dermatitis and asthma and is advancing a Phase 2b/3 study in COPD, positioning tilrekimig as a potentially important next-generation asset in Pfizer’s inflammation and immunology pipeline.
Pfizer reported positive Phase 2 results for tilrekimig, an investigational trispecific antibody being developed for moderate-to-severe atopic dermatitis. The study met its primary endpoint, with all evaluated doses producing statistically significant improvements in EASI-75 skin-clearance rates versus placebo at Week 16.
In Stage 1, 62.5% of patients receiving tilrekimig 450 mg every two weeks achieved EASI-75, compared with 19.9% for placebo. In Stage 2, EASI-75 rates were 58.5% for the 400 mg monthly dose, 61.0% for 200 mg and 47.8% for 50 mg, versus 9.1% for placebo.
Tilrekimig is designed to simultaneously block IL-4, IL-13 and TSLP, targeting multiple pathways involved in type 2 inflammation. Pfizer is also developing the drug with an extended half-life intended to support monthly dosing.
Secondary and exploratory endpoints were also encouraging. Around 26% to 30% of treated patients achieved clear or almost-clear skin depending on dose and study stage, while itch reduction was meaningfully greater than with placebo.
Pfizer said the treatment was generally well tolerated, with no dose-dependent safety signals and no treatment-related serious adverse events reported in the first two stages.
The company has already started Phase 3 trials in atopic dermatitis and asthma and is advancing a Phase 2b/3 study in COPD, positioning tilrekimig as a potentially important next-generation asset in Pfizer’s inflammation and immunology pipeline.
